Pharma Models — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Founded in 2017, Pharma Models is a private, preclinical CRO leveraging deep scientific expertise in animal models to serve pharmaceutical and biotech clients. Its core business is providing fee-for-service studies in cancer and inflammatory diseases, emphasizing custom design, rapid turnaround, and cost-effectiveness. The company is led by experienced scientists and operates in the competitive but growing Boston-area biotech hub, catering to the essential but outsourced need for in vivo validation in early-stage drug development.

OncologyInflammatory DiseasesAutoimmune DiseasesMetabolic Diseases

Technology Platform

Expertise in established animal model systems for oncology, inflammatory diseases, and metabolic disorders; no proprietary AI/ML or drug delivery platform indicated.

Opportunities

The growing trend of biotech outsourcing and the dense concentration of early-stage pharmaceutical companies in the Boston area provide a strong client base.

Increasing R&D focus on complex biologics and immuno-oncology creates demand for specialized in vivo expertise.

Risk Factors

High competition from larger, well-established CROs and academic core facilities.

Revenue is vulnerable to cyclical downturns in biotech funding, particularly in its regional market.

Heavy reliance on a small number of key personnel and a pure service-based model limits scalability and valuation potential.

Competitive Landscape

Operates in a crowded preclinical CRO market competing against global giants (e.g., Charles River Laboratories, Labcorp), mid-sized specialized CROs, and academic research cores. Differentiates through scientist ownership, custom study design, emphasis on affordability, and rapid project initiation, targeting small to mid-sized biotechs.

More companies in Digital Health & Biotech SaaS →More companies in United States →